DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients... Show more
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -0.97% | ||
| ISRG - DXCM | 46% Loosely correlated | +1.42% | ||
| ALGN - DXCM | 44% Loosely correlated | +0.79% | ||
| NVST - DXCM | 40% Loosely correlated | -0.50% | ||
| GKOS - DXCM | 39% Loosely correlated | -0.29% | ||
| PODD - DXCM | 39% Loosely correlated | +0.26% | ||
More | ||||
| Ticker / NAME | Correlation To DXCM | 1D Price Change % |
|---|---|---|
| DXCM | 100% | -0.97% |
| Medical/Nursing Services industry (140 stocks) | 4% Poorly correlated | -0.46% |
| Health Services industry (241 stocks) | 3% Poorly correlated | -0.02% |
DXCM's Aroon Indicator triggered a bullish signal on September 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 187 similar instances where the Aroon Indicator showed a similar pattern. In 139 of the 187 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 74%.
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on DXCM as a result. In 64 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +2.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 207 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for DXCM moved out of overbought territory on August 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 63 cases where DXCM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.469) is normal, around the industry mean (10.859). P/E Ratio (34.237) is within average values for comparable stocks, (99.183). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.049). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (39.828).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.